FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort
HÉRITABILITÉ FAMILIALE, INTERACTIONS GÈNE-GÈNE ET GÈNE-ENVIRONNEMENT DANS LE DOMAINE DES MALADIES CARDIOVASCULAIRES ET RENALES. Cinquième Visite de la Cohorte STANISLAS
2 other identifiers
interventional
3,000
1 country
1
Brief Summary
The Stanislas Cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the Centre for Preventive Medicine of Nancy. This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. The 5th visit of the STANISLAS Cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable cardiovascular-diseases
Started Jul 2023
Longer than P75 for not_applicable cardiovascular-diseases
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 2, 2023
CompletedFirst Posted
Study publicly available on registry
June 23, 2023
CompletedStudy Start
First participant enrolled
July 13, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 13, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 13, 2027
August 15, 2023
August 1, 2023
4 years
June 2, 2023
August 11, 2023
Conditions
Outcome Measures
Primary Outcomes (9)
Indexed left ventricular mass measured by echocardiography
Baseline
Left ventricular volume measured by echocardiography
Baseline
Tissue doppler imaging e' wave measured by echocardiography
Baseline
Ratio E/e' measured by echocardiography
Baseline
Left atrial volume measured by echocardiography
Baseline
Pulmonary congestion evaluated by lung ultrasound
Baseline
Pulse wave velocity measured by Sphygmocor and Complior Analyse
Baseline
Carotid intima media thickness measured by echotracking
Baseline
Central blood pressure
Baseline
Secondary Outcomes (8)
Estimation of the glomerular filtration rate (CKD-EPI formula)
Baseline
Proteinuria (on sample)
Baseline
Blood glucose
Baseline
Change in HbA1C
Baseline
Change in lipid parameters (LDL and HDL cholesterol)
Baseline
- +3 more secondary outcomes
Study Arms (1)
Healthy volonteer
EXPERIMENTALInterventions
Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
EVALOBS scale and compliance questionnaire
For the first 100 patients willing to participate
For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
Patient's evaluation of cardiovascular risk factors by the health system
Assessement of eating habit to create a consumer profile
Evaluation od food supplements intake
Eligibility Criteria
You may qualify if:
- aged over 18
- Person who participated in the Stanislas Cohort
- Person affiliated to a social security scheme or beneficiary of such a scheme
- Person having received complete information on the organization of the research and having signed an informed consent
You may not qualify if:
- Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1
- Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code:
- Pregnant woman, parturient or nursing mother
- Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
- Person of full age unable to express consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHRU de Nancy
Vandœuvre-lès-Nancy, Lorraine, 54500, France
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nicolas Girerd, MD, PhD
Centre d'Investigation Clinique 1433 module Plurithématique - CHRU Nancy
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Coordinating doctor
Study Record Dates
First Submitted
June 2, 2023
First Posted
June 23, 2023
Study Start
July 13, 2023
Primary Completion (Estimated)
July 13, 2027
Study Completion (Estimated)
July 13, 2027
Last Updated
August 15, 2023
Record last verified: 2023-08